NO20054711L - Fremgangsmater og farmasoytiske blandinger for palitelig oppnaelse av akseptable serum-testosteronnivaer - Google Patents

Fremgangsmater og farmasoytiske blandinger for palitelig oppnaelse av akseptable serum-testosteronnivaer

Info

Publication number
NO20054711L
NO20054711L NO20054711A NO20054711A NO20054711L NO 20054711 L NO20054711 L NO 20054711L NO 20054711 A NO20054711 A NO 20054711A NO 20054711 A NO20054711 A NO 20054711A NO 20054711 L NO20054711 L NO 20054711L
Authority
NO
Norway
Prior art keywords
serum testosterone
pharmaceutical compositions
palpable
uptake
methods
Prior art date
Application number
NO20054711A
Other languages
English (en)
Other versions
NO335179B1 (no
NO20054711D0 (no
Inventor
Jan-Peter Ingwersen
Doris Huebler
Sabine Fricke
Wilhelm Kuhnz
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054711(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20054711D0 publication Critical patent/NO20054711D0/no
Publication of NO20054711L publication Critical patent/NO20054711L/no
Publication of NO335179B1 publication Critical patent/NO335179B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Den foreliggende oppfinnelse vedrører farmasøytiske sammensetninger, formulert for injiserbar administrering, som omfatter en testosteronester, særlig testosteron-undecanoate, i en vehikkel som omfatter ricinusolje og et ko-solvent. Ved injeksjon av sammensetningene i henhold til et spesielt administrasjonsregime oppnås det pålitelige nivå av testosteron i serum i det normale fysiologiske området i lange tidsrom. Dette tillater anvendelse av sammensetningene i hormonerstatningsterapi og mannlig prevensjon uten samtidig overvåkning ved en lege av testosteronnivåene i serum.
NO20054711A 2003-03-14 2005-10-13 Farmasøytiske sammensetninger for pålitelig oppnåelse av akseptable serum-testosteronnivåer, samt anvendelse derav NO335179B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300399 2003-03-14
PCT/IB2004/000716 WO2004080383A2 (en) 2003-03-14 2004-03-15 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels

Publications (3)

Publication Number Publication Date
NO20054711D0 NO20054711D0 (no) 2005-10-13
NO20054711L true NO20054711L (no) 2005-12-13
NO335179B1 NO335179B1 (no) 2014-10-13

Family

ID=32748728

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054711A NO335179B1 (no) 2003-03-14 2005-10-13 Farmasøytiske sammensetninger for pålitelig oppnåelse av akseptable serum-testosteronnivåer, samt anvendelse derav

Country Status (39)

Country Link
US (2) US7718640B2 (no)
EP (2) EP1743646A3 (no)
JP (1) JP4680891B2 (no)
KR (2) KR20080096717A (no)
CN (2) CN101884639A (no)
AR (1) AR043603A1 (no)
AT (1) ATE336251T1 (no)
AU (1) AU2004218893B2 (no)
BR (2) BR122017008910A8 (no)
CA (1) CA2518910C (no)
CL (1) CL2004000527A1 (no)
CO (1) CO5700724A2 (no)
CR (1) CR7999A (no)
CY (1) CY1105794T1 (no)
DE (1) DE602004001893T2 (no)
DK (1) DK1457208T3 (no)
EA (1) EA011568B1 (no)
EC (1) ECSP056095A (no)
ES (1) ES2271772T3 (no)
HR (1) HRP20050781B1 (no)
IL (1) IL170473A (no)
IS (1) IS2565B (no)
JO (1) JO2505B1 (no)
ME (2) MEP14508A (no)
MX (1) MXPA04002395A (no)
NO (1) NO335179B1 (no)
NZ (1) NZ542321A (no)
PE (1) PE20041065A1 (no)
PL (1) PL1457208T3 (no)
PT (1) PT1457208E (no)
RS (1) RS51537B (no)
RU (2) RU2354381C2 (no)
SA (1) SA04250040B1 (no)
SI (1) SI1457208T1 (no)
TW (1) TWI345976B (no)
UA (1) UA82510C2 (no)
UY (1) UY28231A1 (no)
WO (1) WO2004080383A2 (no)
ZA (2) ZA200508313B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US8241664B2 (en) * 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
CA2752805A1 (en) 2009-02-18 2010-08-26 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
KR20150011346A (ko) 2012-04-06 2015-01-30 안타레스 팔마, 인코퍼레이티드 테스토스테론 조성물의 바늘-보조식 젯 주입 투여 장치 및 방법
CA2872779A1 (en) * 2012-05-09 2013-11-14 Western University Of Health Sciences Proliposomal testosterone formulations
WO2014093818A2 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
DK2953667T3 (da) * 2013-02-11 2020-01-27 Antares Pharma Inc Nålestøttet jetinjektionsindretning med reduceret udløserkraft
TW201521731A (zh) * 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
WO2015023557A1 (en) 2013-08-12 2015-02-19 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CN105056115A (zh) * 2015-08-05 2015-11-18 成都市飞龙水处理技术研究所 一种治疗化脓性睾丸炎的内服药物及其制备方法
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
US11311554B2 (en) 2018-04-04 2022-04-26 Slayback Pharma Llc Pharmaceutical compositions of testosterone
EP3824296B1 (en) 2018-07-20 2026-04-01 Lipocine Inc. Oral pharmaceutical composition comprising testosterone tridecanoate and/or testosterone dodecanoate for treating liver diseases
KR102051808B1 (ko) * 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
CN113365635A (zh) * 2018-12-14 2021-09-07 阿克罗斯生物制药公司 睾酮的活性酯衍生物、组合物和其用途
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency
WO2021067600A1 (en) * 2019-10-03 2021-04-08 Caren Pharmaceuticals, Inc. Combination hormone formulations and therapies
EP4164743A2 (en) * 2020-06-11 2023-04-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same
US12257257B2 (en) * 2023-07-27 2025-03-25 Lipocine, Inc. Testosterone dodecanoate compositions and methods
KR20250176964A (ko) * 2024-06-13 2025-12-22 주식회사 종근당 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 주사용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4181721A (en) 1975-10-27 1980-01-01 Schering Aktiengesellschaft Depot preparations in an oily, unsaturated solution for intramuscular injection
GB1567515A (en) 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
US4242863A (en) * 1978-03-16 1981-01-06 Caterpillar Tractor Co. Dual phase fuel vaporizing combustor
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) * 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
ATE249206T1 (de) * 1997-12-03 2003-09-15 Merck & Co Inc Langwirkende, injizierbare, formulierungen enthaltend rizinusöl
WO1999067270A1 (en) 1998-06-19 1999-12-29 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
TR200003743T2 (tr) 1998-06-19 2001-07-23 Akzo Nobel N.V. Testosteron türevi.
JP2002541111A (ja) 1999-04-01 2002-12-03 アクゾ・ノベル・エヌ・ベー ウンデカン酸テストステロンとヒマシ油を含む調合物
RU2002124602A (ru) * 2000-02-15 2004-03-10 Шеринг Акциенгезелльшафт (De) Композиция для мужской контрацепции, включающая норэтистерон
MXPA03001147A (es) 2000-08-23 2003-10-06 Akzo Nobel Nv Nueva formulacion de ester de testosterona para uso humano.

Also Published As

Publication number Publication date
CA2518910A1 (en) 2004-09-23
BRPI0400214A (pt) 2005-02-09
CA2518910C (en) 2009-09-08
BRPI0400214A8 (pt) 2023-05-09
DK1457208T3 (da) 2006-12-11
US7718640B2 (en) 2010-05-18
BR122017008910A2 (no) 2005-02-09
DE602004001893D1 (de) 2006-09-28
IL170473A (en) 2010-05-31
US8338395B2 (en) 2012-12-25
US20090156564A1 (en) 2009-06-18
HK1069325A1 (en) 2005-05-20
RU2354381C2 (ru) 2009-05-10
RS20050702A (sr) 2007-06-04
RS51537B (sr) 2011-06-30
JO2505B1 (en) 2009-10-05
HRP20050781B1 (hr) 2015-04-10
ME00149B (me) 2010-06-10
ATE336251T1 (de) 2006-09-15
PT1457208E (pt) 2007-01-31
EP1457208A1 (en) 2004-09-15
AR043603A1 (es) 2005-08-03
JP4680891B2 (ja) 2011-05-11
CO5700724A2 (es) 2006-11-30
BR122017008910A8 (pt) 2023-05-09
WO2004080383A3 (en) 2005-03-31
NO335179B1 (no) 2014-10-13
EP1743646A3 (en) 2007-03-28
NZ542321A (en) 2008-05-30
EP1457208B1 (en) 2006-08-16
US20050032762A1 (en) 2005-02-10
AU2004218893A1 (en) 2004-09-23
WO2004080383A2 (en) 2004-09-23
SA04250040B1 (ar) 2008-01-07
KR100882378B1 (ko) 2009-02-05
PL1457208T3 (pl) 2007-01-31
UY28231A1 (es) 2004-11-08
ZA200508313B (en) 2007-04-25
ES2271772T3 (es) 2007-04-16
EA200501819A1 (ru) 2006-06-30
CL2004000527A1 (es) 2005-02-18
MXPA04002395A (es) 2004-09-20
EA011568B1 (ru) 2009-04-28
PE20041065A1 (es) 2005-02-24
IS2565B (is) 2009-12-15
ECSP056095A (es) 2006-03-01
KR20080096717A (ko) 2008-10-31
RU2007118196A (ru) 2008-11-27
JP2006520377A (ja) 2006-09-07
CY1105794T1 (el) 2011-02-02
TWI345976B (en) 2011-08-01
SI1457208T1 (sl) 2007-02-28
MEP14508A (en) 2010-06-10
CN101884639A (zh) 2010-11-17
NO20054711D0 (no) 2005-10-13
HRP20050781A2 (en) 2005-10-31
WO2004080383B1 (en) 2005-05-06
CN1761469B (zh) 2019-05-17
TW200511997A (en) 2005-04-01
IS8069A (is) 2005-10-12
AU2004218893B2 (en) 2008-10-09
KR20050109561A (ko) 2005-11-21
CN1761469A (zh) 2006-04-19
DE602004001893T2 (de) 2007-03-15
UA82510C2 (uk) 2008-04-25
EP1457208B9 (en) 2006-10-25
ZA200700046B (en) 2008-04-30
CR7999A (es) 2006-05-29
EP1743646A2 (en) 2007-01-17
RU2005131724A (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
TW200511997A (en) Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
WO2007032962A3 (en) Compositions and methods for intranasal delivery of tricyclic cannabinoids
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO950774L (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
NO20091296L (no) Fremgangsmate for behandling av slag med trombolytisk middel
WO2003099992A3 (en) Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
FR2878161B1 (fr) Forme medicamenteuse orale, solide et concue pour eviter le mesusage
TW200518760A (en) Triamcinolone acetonide and anecortave acetate formulations for injection
BR0308229A (pt) Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio
WO2005004854A3 (fr) Utilisation de la betaine pour le traitement des arterites
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)
WO2006012603A3 (en) Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
NO20090368L (no) Cyanocobalamin lav viskositets vandige formuleringer for intranasal avlevering
BRPI0815280A2 (pt) medicamento que compreende uma formulação líquida aquosa de g-csf, receptáculo para a administração de medicamentos líquidos, seringa ou ampola, kit para a administração parenteral de g-csf
BRPI0506710A (pt) composições farmacêuticas de liberação controlada
WO2008009589A3 (en) Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
BRPI0509305A (pt) uso de um sensibilizador insulìnico, composição farmecêutica, e , kit
NO20050352L (no) Medikament for forhindring og/eller behandling av konstipasjon og symptomer pa konstipasjon
MD1568F1 (en) Method of treatment of the burn disease in the burn shock period
PE20020893A1 (es) Composiciones farmaceuticas que comprende pravastatina

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GRUENENTHAL GMBH, DE

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT, DE